Skip to search formSkip to main contentSkip to account menu

Thymidylate Synthase Inhibitor DFP-11207

Known as: DFP-11207, TS Inhibitor DFP-11207 
An orally available thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon oral administration, DFP-11207 binds to and… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors.
3034 Background: DFP-11207 combines a 5-fluorouracil (5-FU) pro-drug with a reversible dihydropyrimidine dehydrogenase inhibitor… 
Review
2017
Review
2017
Abstract 5099: Development of novel antimetabolite, DFP-11207, with self-toxicity protection and its promising preclinical and clinical profiles
Background: For over 50 years, 5-fluorouracil (5-FU) has played a critical role in the systemic chemotherapy of various… 
2016
2016
O3-5-4Phase I study of DFP-11207, a novel chemotherapeutic agent, in patients with solid tumors by reasonable dose escalation
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)